![](/img/cover-not-exists.png)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Harrison, Claire N, Vannucchi, Alessandro M, Platzbecker, Uwe, Cervantes, Francisco, Gupta, Vikas, Lavie, David, Passamonti, Francesco, Winton, Elliott F, Dong, Hua, Kawashima, Jun, Maltzman, Julia D,Language:
english
Journal:
The Lancet Haematology
DOI:
10.1016/S2352-3026(17)30237-5
Date:
December, 2017
File:
PDF, 533 KB
english, 2017